IT HAS BEEN XaEt' ORTED that, when administered alone, the hvo clinically available narcotic antagonists, nalorphine hydrochloride (Nalline) 1-7 and levallorphan tartrate, 8-1~ have respiratory and circulatory effects similar to those of narcotics. When a third potent narcotic antagonist, naloxone hydrochloride, became available for experimental use, it seemed worthwhile to compare the respiratory and circulatory effects of equipotent doses 11,1~ of these three compounds under identical conditions in man. While it obtained information of pharmacological interest, the main goal of this study was to determine which of these three compounds has the least liability to respiratory and circulatory side effects and is therefore preferable for clinical use.
To minimize carbon dioxide accumulation and to provide adequate oxygenation, assisted or controlled respiration was used, the latter when the subjects became apnoeic (did not breathe spontaneously for 30 seconds). For 30 seconds before and during each one-minute observation period, however, the patients were allowed to breathe spontaneously. During this time the flow rates of nitrous oxide and oxygen were each reduced to 500 ml/min.
After the determination of control values of the respiratory and circulatory parameters, subjects in group I received 20 /~g/kg oxymorphone hydrochloride (Numorphan) in 30 seconds. Those in groups II, III, and IV received in 30 seconds comparable doses of the three antagonists: 12 150 /~g/kg nalorphine hydrochloride (Nalline), 20/zg/kg levallorphan tartrate (Loffan), and 5/xg/kg naloxone hydrochloride respectively. The subjects of group V were given the double (10/zg/kg) dose of naloxone. Five minutes after the start of the injection of the narcotic antagonist, the subjects of groups II, III, IV, and V received 20/zg/kg oxymorphone.
The various respiratory and circulatory parameters were again determined at three minutes after the administration of the narcotic antagonists and at three, six, and ten minutes after the start of injection of oxymorphone. The respiratory parameters were observed during a one-minute period starting 30 seconds before and ending 30 seconds after the times indicated. All observations were expressed as percentages of control values. Those few cases in which partial obstruction of the airway developed were not included. In a few cases, the reservoir bag of the anaesthesia machine was replaced by a Sanborn metabolizer, and respiratory tracings were made before and after the administration of the various antagonists and oxymorphone.
RESULTS
The intravenous administration of 150/zg/kg of nalorphine or 20/zg/kg levallorphan produced a highly significant (p < 0.001 ) decrease of the respiratory rate and minute volume in three minutes (Figs. 1 and 2; Tables I and II ) . The depression of the tidal volume was transient (Figs. 3 and 4) , and within three minutes it returned to control value ( Fig. 5 and Table III ). In contrast, the administration of 5 or 10/zg/kg naloxone caused an insignificant change in these parameters (Figs. 1, 2, 3, and 6; Tables I, II, and III) .
The circulatory effects of the three narcotic antagonists were similar and less marked. The pulse rate was decreased somewhat more by levallorphan than by the other two antagonists ( Fig. 7 and Table IV ). The effect of the three antagonists on systolic blood pressure, however, was about the same ( Fig. 8 and Table V) .
The administration of 20/zg/kg oxymorphone caused a highly significant (p < 0.001) decrease of respiratory rate, minute volume, and systolic blood pressure (Tables I and III ) and a less marked but still significant (p < 0.02) decrease of pulse rate (Table IV) . These changes were maintained throughout the tenminute observation period. The administration of nalorphine and levallorphan five minutes before the start of injection of oxymorphone did not afford significant protection against the depression of the respiratory rate (Table 1) . Nalorphine (p < 0.01), but not levallorphan, had a significant protective effect against the depression of the minute volume. In contrast, the protective effect of both 5 and 10 Fg/kg naloxone on the oxymorphone-induced depression of the respiratory rate (p < 0.01 and 0.001 for the smaller and larger dose respectively), and the minute volume (p < 0.001 for both doses) was statistically significant ( Tables I and II) .
None of the narcotic antagonists influenced the slowing of the pulse rate caused by oxymorphone. The protective effect of nalorphine and naloxone against oxymorphone-induced decrease of the systolic blood pressure, however, was significant (p < 0.05) throughout the experimental period, and that of levallorphan was significant at ten minutes after the administration of oxymorphone.
DLSCUSSION
The results of the present study indicate that 5/zg/kg naloxone has a greater protective effect on oxymorphone-induced respiratory depression than 150/xg/kg nalorphine or 20/zg/kg levallorphan. This is in keeping with previous findings that when the same doses of these narcotic antagonists were used to counteract respiratory depression caused by five different narcotics, naloxone was the most effective. TM Doubling the dose of naloxone (to 10/zg/kg) increased the protective effect, but the increase was not statisUcally significant. When administered to subjects who had not received a narcotic previously, these doses of naloxone caused no respiratory depression. In contrast, under similar circumstances, doses of nalorphine (150 pg/kg) or levallorphan (20/~g/kg) commonly used to antagonize narcotic-induced respiratory depression caused a significant decrease of respiratory rate and minute volume (Tables I and II) . Thus, for example, 150 /zg/kg nalorphine and 200/zg/kg morphine sulphate 1-~ caused comparable decrease of these parameters. FrctraE 6. The effect on respiration of naloxone followed by oxymorphone. Note that in contrast to nalorphine and levallorphan, naloxone does not decrease respiratory rate, tidal volume, or minute volume.
Jasinski et al. 1~ observed that several pharmacologic and psychopharmacologie actions of naloxone are qualitatively different from those of nalorphine and leval-]orphan. Thus, in contrast to nalorphine, levallorphan, and cyclazocine, naloxone does not constrict the pupils, does not have psychotomimetic or sedative effects, and during or after chronic administration it does not cause any physiologic and behavioural changes, or physical dependence. It was also observed that naloxone retained the desirable properties of narcotic antagonists. It antagonized the effects of morphine injected one, two, and four hours after its administration and, on a mg/kg basis, its ability to precipitate abstinence was found to be about seven times greater than that of nalorphine. On chronic administration no tolerance developed to its desirable effects.
The data summarized in Table VI indicate that naloxone possesses all the desirable therapeutic effects, and is free from the unwanted side effects of narcotic antagonists. This separation of the desirable and the undesirable effects makes naloxone the narcotic antagonist of choice for clinical use, especially when the cause of the respiratory depression is not definitely known (e.g. in the neonate whose mother has received narcotics, or in attempted suicide with an unknown central nervous system depressant). Under these circumstances, all narcotic antagonists will antagonize the respiratory depression ff it is narcotic-induced. If, however, it is due to other causes, e.g. inhalation anaesthetic agents, barbiturates, hypoxia, cerebrovascular accidents, brain injury, while nalorphine and levallorphan will increase respiratory depression, naloxone will cause no further deterioration. Since doses of naloxone ( 170 gg/kg) up to fifteen times higher than those (5 to 10/zg/kg) found adequate to prevent narcotic-induced respiratory and circulatory depression had no demonstrable psychotomimetie or sedative effects in conscious subjects, it is less likely that those unwanted side effects will be encountered in patients who receive naloxone at the termination of anaesthesia.
For the same reason, there should be no hesitation to administer repeated doses of naloxone to patients intoxicated with excessive doses of narcotic analgesics.
SUMMARY
Nalorphine ( 150 ~g/kg) and levallorphan (20 ~g/kg), when administered to lightly anaesthetized subjects who had not received a narcotic, caused significant depression of respiratory rate and minute volume. In contrast, 5 and 10/~g/kg naloxone caused no respiratory depression. These doses of nalorphine, levalIorphan, and naIoxone caused a moderate decrease of pulse rate and systolic blood pressure. Naloxone 5 and i0 ~g/kg offered significantly greater protection against the respiratory depressant effects of 20 ~g/kg oxymorphone administered five minutes later than 150 ~g/kg nalorphine or 20 ~g/kg levallorphan. None of the three narcotic antagonists affected the oxymorphone-induced decrease of pulse rate, and all had about the same protective effect against the fall of systolic blood pressure caused by this compound. Since doses of naloxone, which provide significantly better protection against narcotic-induced respiratory depression than the conventional doses of nalorphine and leva]]orphan, cause no respiratory depression in themselves, it should be considered the narcotic antagonist of choice for clinical use. l~sv~n~ La nalorphine (150/zg/kg) et la levallorphan (20/zg/kg), administr~s ~ des suiets sous anesth~sie l~g~re et qui n'avaient pas regu de narcotique, ont produit une d~pression marquee du rythme respiratoire et du volume minute. Par contre,
